Goldman Sachs Alum Sounds Alarm on "Next US Crisis"
Few believed Nomi Prins when she called the 2008 meltdown well in advance. Now, she's issuing a new prediction. Most Americans aren't yet prepared.
Learn more.
Derek Jantz net worth and biography

Derek Jantz Biography and Net Worth

Derek Jantz is the Chief Scientific Officer of Precision BioSciences. He co-founded the company in 2006 after co-inventing a novel method for modifying the DNA-recognition properties of the I-CreI homing endonuclease. This early work is the foundation of Precision’s ARCUS genome editing platform, which has been used to develop clinical-stage oncology therapeutics as well as a robust pipeline of pre-clinical cell and gene therapies. Trained as a protein engineer, Derek was an early developer of zinc finger technology and spent most of his research career designing proteins for genome editing applications. At Precision, Derek is responsible for all research programs and also supports business and corporate development. He serves on the senior leadership team and is a member of the board of directors. When he is not making critical decisions, Derek enjoys writing holiday themed poetry and finding ways to slip sci-fi references into corporate presentations.

What is Derek Jantz's net worth?

The estimated net worth of Derek Jantz is at least $4.95 million as of June 8th, 2022. Dr. Jantz owns 4,055,174 shares of Precision BioSciences stock worth more than $4,947,312 as of September 26th. This net worth approximation does not reflect any other investments that Dr. Jantz may own. Additionally, Dr. Jantz receives an annual salary of $597,380.00 as Insider at Precision BioSciences. Learn More about Derek Jantz's net worth.

How old is Derek Jantz?

Dr. Jantz is currently 46 years old. There are 4 older executives and no younger executives at Precision BioSciences. The oldest executive at Precision BioSciences is Mr. John Alexander Kelly, Chief Financial Officer, who is 55 years old. Learn More on Derek Jantz's age.

What is Derek Jantz's salary?

As the Insider of Precision BioSciences, Inc., Dr. Jantz earns $597,380.00 per year. There are 2 executives that earn more than Dr. Jantz. The highest earning executive at Precision BioSciences is Mr. Michael Amoroso, Pres, CEO & Director, who commands a salary of $876,240.00 per year. Learn More on Derek Jantz's salary.

How do I contact Derek Jantz?

The corporate mailing address for Dr. Jantz and other Precision BioSciences executives is 302 EAST PETTIGREW STREET SUITE A-100, DURHAM NC, 27701. Precision BioSciences can also be reached via phone at (919) 314-5512 and via email at [email protected] Learn More on Derek Jantz's contact information.

Has Derek Jantz been buying or selling shares of Precision BioSciences?

Derek Jantz has not been actively trading shares of Precision BioSciences over the course of the past ninety days. Most recently, Derek Jantz sold 18,849 shares of the business's stock in a transaction on Wednesday, June 8th. The shares were sold at an average price of $2.06, for a transaction totalling $38,828.94. Following the completion of the sale, the insider now directly owns 4,055,174 shares of the company's stock, valued at $8,353,658.44. Learn More on Derek Jantz's trading history.

Who are Precision BioSciences' active insiders?

Precision BioSciences' insider roster includes Derek Jantz (Insider), Matthew Kane (CEO), and David Thomson (COO). Learn More on Precision BioSciences' active insiders.

Are insiders buying or selling shares of Precision BioSciences?

In the last twelve months, Precision BioSciences insiders bought shares 2 times. They purchased a total of 50,461 shares worth more than $102,041.16. In the last twelve months, insiders at the sold shares 3 times. They sold a total of 36,457 shares worth more than $75,412.42. The most recent insider tranaction occured on June, 22nd when CFO John Alexander Kelly bought 33,784 shares worth more than $50,676.00. Insiders at Precision BioSciences own 8.5 % of the company. Learn More about insider trades at Precision BioSciences.

Information on this page was last updated on 6/22/2022.

Derek Jantz Insider Trading History at Precision BioSciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/8/2022Sell18,849$2.06$38,828.944,055,174View SEC Filing Icon  
5/17/2021Sell20,000$9.38$187,600.004,032,279View SEC Filing Icon  
5/12/2021Sell9,676$8.72$84,374.724,038,273View SEC Filing Icon  
4/19/2021Sell9,676$8.69$84,084.444,026,435View SEC Filing Icon  
3/17/2021Sell9,665$10.92$105,541.803,967,207View SEC Filing Icon  
2/19/2021Sell9,663$11.55$111,607.653,928,859View SEC Filing Icon  
1/29/2021Sell6,444$12.25$78,939.003,913,789View SEC Filing Icon  
1/27/2021Sell7,048$11.68$82,320.643,884,252View SEC Filing Icon  
See Full Table

Derek Jantz Buying and Selling Activity at Precision BioSciences

This chart shows Derek Jantz's buying and selling at Precision BioSciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Precision BioSciences Company Overview

Precision BioSciences logo
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Read More

Today's Range

Now: $1.22
Low: $1.18
High: $1.27

50 Day Range

MA: $1.62
Low: $1.22
High: $2.06

2 Week Range

Now: $1.22
Low: $1.11
High: $13.20


985,900 shs

Average Volume

1,631,943 shs

Market Capitalization

$135.20 million

P/E Ratio


Dividend Yield



Goldman Sachs Alum Sounds Alarm on "Next US Crisis"
Few believed Nomi Prins when she called the 2008 meltdown well in advance. Now, she's issuing a new prediction. Most Americans aren't yet prepared.
Learn more.